Long-Acting Thyroid Stimulator (LATS)

Subscribe to Selected New Research on Long-Acting Thyroid Stimulator

233 relevant articles (0 outcomes, 22 trials/studies) found for this Bio-Agent

Description: An immunoglobulin G, often found in the blood of hyperthyroid individuals. It stimulates the thyroid for a longer duration than does thyrotoxin and may cause hyperthyroidism in newborns due to placental transmission.

Also Known As:

LATS; Long Acting Thyroid Stimulator; Stimulator, Long-Acting Thyroid; Thyroid Stimulator, Long Acting; Thyroid Stimulator, Long-Acting

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Globulins: 305

Serum Globulins: 74

Immunoglobulins: 20136

Antibodies: 77322

Autoantibodies: 14185

Thyroid-Stimulating Immunoglobulins: 427

Long-Acting Thyroid Stimulator: 233

long-acting thyroid stimulator protector: 25

Immunoglobulin Isotypes: 348

Immunoglobulin G: 31640

Long-Acting Thyroid Stimulator: 233

long-acting thyroid stimulator protector: 25

Experts

1.	Yee, Jiing-Kuan: 1 article (04/2007)
2.	Dammann, Reinhard: 1 article (04/2007)
3.	Liu, Limin: 1 article (04/2007)
4.	Guo, Cai: 1 article (04/2007)
5.	Pfeifer, Gerd P: 1 article (04/2007)
6.	Tommasi, Stella: 1 article (04/2007)
7.	Cohen, Stephen: 1 article (09/2005)
8.	Wernet, Mathias F: 1 article (09/2005)
9.	Pistillo, Daniela: 1 article (09/2005)
10.	Chen, Ya-Wen: 1 article (09/2005)

Related Diseases

1.	Graves Disease (Basedow Disease) 05/01/1984 - "Overall, the study indicates that serum LATS-P is related to the clinical course of Graves' disease but there remains a minority of patients in whom the activity cannot be detected." 04/01/1997 - "Members of the Latin American Thyroid Society (LATS) (235 physicians) were surveyed by a questionnaire on their management of Graves' disease, and the survey procedure was the same used by the other thyroid societies. " 06/01/1986 - "Changes in c-TRAb, p-TRAb and LATS activity in the clinical course of patients with Graves' disease were examined. " 06/01/1984 - "The positive TRAb was not changed in 4 Graves' disease patients whose LATS activity had disappeared following antithyroid treatment. " 06/01/1981 - "The prevalence of serum LATS and LATS-P in untreated Graves' disease has been studied in eighty-three patients with thyroid overactivity; twelve (14%) were found to have significant levels of LATs and LATS-P whilst fifty-nine (72%) had significant levels of LATS-P alone. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 11/03/2009 - "BACKGROUND: Human MST/hSAV/LATS/hMOB tumor suppressor cascades are regulators of cell death and proliferation; however, little is known about other functions of MST/hMOB signaling. " 09/10/2009 - "LATS2 is a member of the LATS tumor suppressor family. " 02/29/2008 - "Drosophila or mice mutant for LATS develop tumors in various tissues. " 04/17/2007 - "RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network." 10/15/2004 - "In a genetic background heterozygous for lats, a Drosophila and vertebrate tumor suppressor gene, homozygous inactivation of Mnn1 enhanced somatic mutation of the second allele of lats and formation of multiple primary tumors. " Order ALL the reference details at left...
3.	Warts (Wart) 09/09/2005 - "The growth regulators warts/lats and melted interact in a bistable loop to specify opposite fates in Drosophila R8 photoreceptors." 09/15/2004 - "The Drosophila melanogaster warts/lats tumour suppressor has two mammalian counterparts LATS1/Warts-1 and LATS2/Kpm. " 11/01/2002 - "Recently, LATS2, a new human homologue of the Drosophila tumor suppressor gene (lats/warts) was identified on 13q11-12. " 06/22/2000 - "Among these, kpm is most homologous to, but distinct from, recently reported LATS1, a human homolog of Drosophila warts/lats. " 01/15/2000 - "We have cloned and characterized LATS2, a novel mammalian homologue of the Drosophila tumor suppressor gene lats/warts. " Order ALL the reference details at left...
4.	Infection 04/01/2006 - "Our study assessed MRSA burden in Texas 4A and 5A high school athletic departments by contacting 447 licensed athletic trainers (LATs) regarding skin infections in athletes; 186 (41.6%) responded. " 09/15/1996 - "At survival times of > 30 d after inoculation, we found that (1) infectious virus was not detectable by titration and immunohistochemical studies; (2) neurons harbored virus as demonstrated by the detection of the LATs by in situ hybridization (ISH); (3) transcripts expressed during the lytic cycle of infection were not detected by ISH; and (4) subsets of neurons were selectively vulnerable to latent infection, depending on the site of inoculation. " 12/01/1991 - "Many recent studies of latent herpes simplex virus type 1 (HSV-1) infections within the nervous system have focused on the diploid genes encoding the latency-associated transcripts (LATs). " 02/01/2008 - "We propose that cycles of infection and reactivation occur in the initial stages of infection that produce high levels of mB(Lats) in the circulation. " 12/05/2006 - "The latency-associated transcripts (LATs) of herpes simplex virus type-1 (HSV-1) are the only viral RNAs accumulating during latent infections in the sensory ganglia of the peripheral nervous system. " Order ALL the reference details at left...
5.	Thyrotoxicosis 03/01/1980 - "These studies suggest that in women with a history of thyrotoxicosis, high levels of maternal LATS may in some instances provoke fetal thyrotoxicosis, which can be diagnosed by the measurement of amniotic fluid reverse T3." 05/01/1978 - "With this method, 7 out of 32 patients with thyrotoxicosis showed LATS and 18 showed LATSP. " 09/01/1975 - "One women had inadvertently received a therapeutic dose of radioiodine at 21 weeks gestation and the other suffered from severe thyrotoxicosis with a serum LATS level of 1850%. " 07/01/1975 - "These results raise doubts about a direct causative role for LATS in most cases of thyrotoxicosis." 07/01/1975 - "The distribution of the results of LATS assays in the hypopituitary patients was significantly different from that in the normal subjects; 4 out of 27 hypopituitary patients had LATS levels above the normal range, although they had no thyrotoxicosis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Long-Acting Thyroid Stimulator (LATS)
2.	Phosphotransferases (Kinase)
3.	Antibodies
4.	Antigens
5.	Thyroid-Stimulating Immunoglobulins
6.	Protein Kinases (Protein Kinase)
7.	Immunoglobulin G (IgG)
8.	Hormones
9.	Thyrotropin Receptors (Thyrotropin Receptor)
10.	Viral DNA

Related Therapies and Procedures

1.	Thyroidectomy
2.	Hypophysectomy

Best Treatments:
Research Summary Report
on Graves Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 217 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>